Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock fell -2.70% on Monday to $6.86 against a previous-day closing price of $7.05. With 4.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.7 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.23 whereas the lowest price it dropped to was $6.82. The 52-week range on RXRX shows that it touched its highest point at $16.75 and its lowest point at $4.54 during that stretch. It currently has a 1-year price target of $15.57. Beta for the stock currently stands at 0.43.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RXRX was up-trending over the past week, with a rise of 17.67%, but this was up by 14.91% over a month. Three-month performance dropped to -24.45% while six-month performance fell -15.52%. The stock lost -37.18% in the past year, while it has lost -11.02% so far this year. A look at the trailing 12-month EPS for RXRX yields -1.47 with Next year EPS estimates of -1.85. For the next quarter, that number is -0.45. This implies an EPS growth rate of -18.20% for this year and -14.85% for next year.
Float and Shares Shorts:
At present, 183.21 million RXRX shares are outstanding with a float of 150.44 million shares on hand for trading. On Oct 30, 2023, short shares totaled 33.05 million, which was 15.31% higher than short shares on Sep 28, 2023. In addition to Dr. Christopher C. Gibson Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Tina Marriott Larson serves as its COO & President.
Through their ownership of 88.93% of RXRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.25% of RXRX, in contrast to 23.10% held by mutual funds. Shares owned by individuals account for 21.27%. As the largest shareholder in RXRX with 12.03% of the stake, Baillie Gifford & Co. holds 24,551,409 shares worth 24,551,409. A second-largest stockholder of RXRX, The Vanguard Group, Inc., holds 15,269,962 shares, controlling over 7.48% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in RXRX, holding 11,757,088 shares or 5.76% stake. With a 7.86% stake in RXRX, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 16,029,227 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 4.71% of RXRX stock, is the second-largest Mutual Fund holder. It holds 9,608,469 shares valued at 50.73 million. ARK Genomic Revolution ETF holds 4.09% of the stake in RXRX, owning 8,343,944 shares worth 44.06 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RXRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RXRX analysts setting a high price target of $35.00 and a low target of $9.00, the average target price over the next 12 months is $15.57. Based on these targets, RXRX could surge 410.2% to reach the target high and rise by 31.2% to reach the target low. Reaching the average price target will result in a growth of 126.97% from current levels.
Summary of Insider Activity:
Insiders traded RXRX stock several times over the past three months with 9 Buys and 12 Sells. In these transactions, 108,198 shares were bought while 121,425 shares were sold. The number of buy transactions has increased to 94 while that of sell transactions has risen to 94 over the past year. The total number of shares bought during that period was 3,278,146 while 1,735,494 shares were sold.